Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study (NEOPAC Study)

NCT01314027 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT01314027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01314027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study (NEOPAC Study)
Lead sponsor
University of Zurich
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2009
Completion date
May 31, 2019
Enrollment
38 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer